General News OXURION to Present Clinical and Pre-Clinical Data at Upcoming EURETINA 2021 Virtual Congress EN September 8, 2021
General News Oxurion NV – Publication of Positive Phase 1 Clinical Data evaluating THR-687 for Treatment of DME in Ophthalmology Science, the American Academy of Ophthalmology Journal EN August 17, 2021
General News Oxurion NV – Journal of Pharmacokinetics and Pharmacodynamics highlights desirable PK/PD profiles of THR-687 and THR-149 EN August 16, 2021
General News OXURION Confirms Institutional Review Board Approval and Submission of the Investigational New Drug Application to the FDA to Start Phase 2 Study Evaluating THR-687 for Diabetic Macular Edema (DME) EN June 10, 2021
General News OXURION Completes Patient Enrollment for Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME) EN June 8, 2021
General News Oxurion NV – Publication in ‘Progress in Retinal and Eye Research’ highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD EN April 7, 2021
General News Oxurion NV enters into a Capital Commitment of up to €30 Million with Negma Group EN April 6, 2021
General News Regulated Oxurion NV appoints Prof Alan Stitt as Chief Scientific Officer EN January 20, 2021
General News Regulated OXURION NV Confirms New Patents for THR-687 Issued by European and US Patent Offices EN November 9, 2020
